Clinical Trials Logo
  1. Home
  2. Neutropenia, Febrile
  3. NCT04938206

DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule — DISCERN-FN7  

Neutropenia, Febrile Clinical Trial

Official title:
DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule

Clinical Trial Summary

Febrile neutropenia (NF) is the leading cause of unscheduled hospitalization in children with cancer. Management classically involves emergency admission to hospital for intravenous antibiotic treatment until resolution of fever and neutropenia. However, children with NF are a heterogeneous group with varying risks of severe infection (10-29%). This approach, which is recognized as excessive for low-risk episodes of severe infection, particularly in terms of quality of life and cost, is no longer recommended. Management should move to a more personalized model that takes into account the individual probability of severe infection. Clinical decision rules (CDRs) have been proposed to facilitate risk stratification, but none are useful in our French population because of insufficient reproducibility or effectiveness.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04938206
Study type Interventional
Source University Hospital, Lille
Contact François Dubos, MD,PhD
Phone (3) 20 44 59 20
Email francois.dubos@chru-lille.fr
Status Recruiting
Phase N/A
Start date January 27, 2021
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04637464 - Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer N/A
Completed NCT03511820 - A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever
Not yet recruiting NCT04260230 - Remote Monitoring of Patients at Risk of Sepsis N/A
Completed NCT04187755 - Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever Phase 4
Completed NCT03217721 - Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit N/A
Completed NCT04669418 - Host RNA Signature in Children With Cancer and Infection
Terminated NCT03003273 - Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study Phase 3
Recruiting NCT05926063 - Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia Phase 4
Not yet recruiting NCT05852249 - Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.
Withdrawn NCT05061654 - CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Phase 4
Recruiting NCT02474550 - Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma N/A